|
|
|
|
|
||
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online 1 February 2005
doi: 10.1242/jcs.01653
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Article |
Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center, 79106 Freiburg, Germany
* Author for correspondence (e-mail: augustin{at}angiogenese.de)
Accepted 17 November 2004
The angiopoietins Ang-1 and Ang-2 have been identified as ligands of the endothelial receptor tyrosine kinase Tie-2, which controls vascular assembly and endothelial quiescence. The largely complementary phenotypes of Ang-1-deficient mice and Ang-2-overexpressing mice have led to an antagonistic model in which Ang-1 acts as Tie-2-activating agonist and Ang-2 acts as a Tie-2-inhibiting antagonist. To date, no mechanistic equivalent of the antagonistic Ang-1/Ang-2 model has been established and the mechanisms of Ang-2 function in particular remain mysterious. We have studied the effector functions of Ang-1 and Ang-2 on quiescent endothelial cells using a three-dimensional co-culture model of endothelial cells and smooth-muscle cells. Endothelial-cell monolayer integrity in this model is dependent on Tie-2 signaling, as evidenced by detaching endothelial cells following exposure to the small molecular weight Tie-2 inhibitor A-422885.66, which cannot be overcome by exogenous Ang-1. Accordingly, exogenous Ang-2 rapidly destabilizes the endothelial layer, which can be observed within 30-60 minutes and leads to prominent endothelial-cell detachment within 4 hours. Exogenous Ang-2-mediated endothelial-cell detachment can be rescued by Ang-1, soluble Tie-2 and vascular endothelial growth factor. Similar findings were obtained in an umbilical-vein explant model. Ang-2 is mainly produced by endothelial cells and therefore acts primarily in an autocrine manner. Thus, stimulated release of endogenous Ang-2 or overexpression of Ang-2 in endothelial cells perturbs co-culture spheroid integrity, which can be rescued by exogenous Ang-1 and vascular endothelial growth factor. However, autocrine Ang-2-mediated endothelial-cell detachment cannot be blocked by soluble Tie-2. Taken together, the data demonstrate for the first time the antagonistic Ang-1/Ang-2 concept in a defined cellular model and identify Ang-2 as a rapidly acting autocrine regulator of the endothelium that acts through an internal autocrine loop mechanism.
Key words: Angiopoietin, Endothelial cells, Angiogenesis
This article has been cited by other articles:
|
|
 |
|
  T. Kohno, T. Daa, H. Otani, I. Shimokawa, S. Yokoyama, and T. Matsuyama Aberrant expression of BAFF receptor, a member of the tumor necrosis factor receptor family, in malignant cells of nonhematopoietic origins Genes Cells, October 1, 2008; 13(10): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M van der Heijden, G P van Nieuw Amerongen, P Koolwijk, V W M van Hinsbergh, and A B J Groeneveld Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients Thorax, October 1, 2008; 63(10): 903 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kumpers, C. Koenecke, H. Hecker, J. Hellpap, R. Horn, W. Verhagen, S. Buchholz, B. Hertenstein, J. Krauter, M. Eder, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Blood, September 1, 2008; 112(5): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anargyrou, E. Terpos, T. P. Vassilakopoulos, A. Pouli, S. Sachanas, T. Tzenou, S. Masouridis, D. Christoulas, M. K. Angelopoulou, E. M. Dimitriadou, et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib Haematologica, March 1, 2008; 93(3): 451 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lan, B. Liu, H. Yao, F. Li, T. Weng, G. Yang, W. Li, X. Cheng, N. Mao, and X. Yang Essential Role of Endothelial Smad4 in Vascular Remodeling and Integrity Mol. Cell. Biol., November 1, 2007; 27(21): 7683 - 7692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Liu, J. Wang, B. Kinzel, M. Mueller, X. Mao, R. Valdez, Y. Liu, and E. Li Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity Blood, September 1, 2007; 110(5): 1502 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. de Caestecker Angiopoietin-2 and Glomerular Proteinuria J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2217 - 2218. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications Am. J. Pathol., January 1, 2007; 170(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Daly, E. Pasnikowski, E. Burova, V. Wong, T. H. Aldrich, J. Griffiths, E. Ioffe, T. J. Daly, J. P. Fandl, N. Papadopoulos, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells PNAS, October 17, 2006; 103(42): 15491 - 15496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pfaff, U. Fiedler, and H. G. Augustin Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking J. Leukoc. Biol., October 1, 2006; 80(4): 719 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kalomenidis, A. Kollintza, I. Sigala, A. Papapetropoulos, S. Papiris, R. W. Light, and C. Roussos Angiopoietin-2 Levels Are Elevated in Exudative Pleural Effusions Chest, May 1, 2006; 129(5): 1259 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P.J. Brindle, P. Saharinen, and K. Alitalo Signaling and Functions of Angiopoietin-1 in Vascular Protection Circ. Res., April 28, 2006; 98(8): 1014 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Phelps, D. L. Updike, E. C. Bullen, P. Grammas, and E. W. Howard Transcriptional and posttranscriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells Am J Physiol Cell Physiol, February 1, 2006; 290(2): C352 - C361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Fathers, C. M. Stone, K. Minhas, J. J.A. Marriott, J. D. Greenwood, D. J. Dumont, and B. L. Coomber Heterogeneity of Tie2 Expression in Tumor Microcirculation: Influence of Cancer Type, Implantation Site, and Response to Therapy Am. J. Pathol., December 1, 2005; 167(6): 1753 - 1762. [Abstract] [Full Text] [PDF]
|
|
